The 340B discount program—which requires manufacturers to provide outpatient drugs to eligible health care entities at sharply reduced prices—continues to be both controversial and confusing. Manatt’s new webinar will explain the latest developments in the 340B program, including:
- The impact the drug pricing provisions in the Inflation Reduction Act will have on the 340B program
- The current state of manufacturer restrictions on the shipment of 340B drugs to contract pharmacies
- State-level efforts to prohibit health plans and pharmacy benefit managers (PBMs) from reimbursing or otherwise treating 340B covered entities and/or 340B contract pharmacies differently from health care providers and pharmacies that do not participate in the 340B program
In addition, the session will share—for the first time—the results of Manatt’s new survey tracking 340B antidiscrimination legislation by state.